Intelligence · Patents
Patents expiring in 2034
Annual patent cliff calendar for 2034 — US pharmaceutical patents by expiration date.
- Patents
- 1,452
Quick answer
1,452 indexed pharmaceutical patents have expiration dates in 2034. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 8680094
1, 4-benzoxazine compounds and derivatives thereof as therapeutic drugs for the treatment of neurodegenerative conditions
granted -
US 8680132
Spiro-oxindole MDM2 antagonists
granted -
US 8680319
Method for producing antifolate agents having glutamic acid part in their structure
granted -
US 8680084
Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
granted -
US 8680291
Diarylhydantoin compounds
granted -
US 8680263
Carbohydrate-based drug delivery polymers and conjugates thereof
granted -
US 8680065
Oligonucleotides of human endogenous retrovirus 9 (ERV-9) long terminal repeat (LTR) and methods of use
granted -
US 8680150
Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
granted -
US 8680131
Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
granted -
US 8680115
Tetrahydroquinoline analogues as muscarinic agonists
granted -
US 8680113
BMI-1 protein expression modulators
granted -
US 8680082
Controlled release corticosteroid compositions and methods for the treatment of otic disorders
granted -
US 8680066
Methods for determining and inhibiting rheumatoid arthritis associated with the BRAF oncogene in a subject
granted -
US 8680056
Antiproliferative factor and methods of use
granted -
US 8680046
Inhibitors of viral integrase and methods of use
granted -
US 8680021
Zinc finger proteins for DNA binding and gene regulation in plants
granted -
US 8679557
Synergistic herbal ophthalmic formulation for lowering the intra ocular pressure in case of glaucoma
granted -
US 8680022
Methods and compositions
granted -
US 8679545
Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
granted -
US 8679489
Inhibiting cell migration
granted -
US 8679476
Interferon-β production modulating Listeria strains and methods for using same
granted -
US 8686157
Processes for the facile synthesis of diaryl amines and analogues thereof
granted -
US 8686143
Compounds useful as inhibitors of Janus kinases
granted -
US 8686184
Neprilysin inhibitors
granted -
US 8686045
Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
granted -
US 8686016
Schweinfurthins and uses thereof
granted -
US 8686010
Aryl- or heteroaryl-sulfonyl compounds as acid secretion inhibitors
granted -
US 8685973
Pyrimidine cyclohexyl glucocorticoid receptor modulators
granted -
US 8685936
Sphingosine kinase inhibitor prodrugs
granted -
US 8686012
Stem cell differentiating agents and uses therefor
granted -
US 8685979
Oligomer-diarylpiperazine conjugates
granted -
US 8685734
Viral purification methods
granted -
US 8685931
Hair growth methods using FGFR3 extracellular domains
granted -
US 8685917
Cyclosporin analogues
granted -
US 8685929
Detecting CYP24 expression level as a marker for predisposition to cancer
granted -
US 8685890
Multispecific peptides
granted -
US 8685722
Bovine adeno-associated viral (BAAV) vector and uses thereof
granted -
US 8685416
Compositions and methods for the treatment of cancer
granted -
US 8685411
Rotavirus antigens
granted -
US 8685396
Monoclonal antibodies that neutralize anthrax protective antigen (PA) toxin
granted -
US 8685538
Stable polyelectrolyte coated nanoparticles
granted -
US 8685406
Compositions of and method of using heat shock protein peptides
granted -
US 8685383
Protein-polymer-drug conjugates
granted -
US 8685403
Insulin-like growth factor signaling and integrin
granted -
US 8685372
Peptides and aptamers for targeting of neuron or nerves
granted -
US 8685924
Preventives/remedies for stress urinary incontinence and method of screening the same
granted -
US 8685404
Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction
granted -
US 8685926
Compositions and method for CaMKII inhibitors and uses thereof
granted
Frequently asked questions
How many pharma patents expire in 2034?
1,452 published patents in our USPTO index have expiration dates falling in calendar year 2034.